Rdea119, a potent and highly selective MEK inhibitor ameliorates marine colitis

被引：0
|
作者：
Miampamba, Marcel
机构：
来源：
GASTROENTEROLOGY | 2008年 / 134卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A107 / A107
页数：1
相关论文
共 50 条
  • [1] RDEA119, a potent and highly selective MEK1/2 inhibitor is beneficial in dextran sulfate sodium (DSS)-induced chronic colitis in mice
    Miampamba, Marcel
    Larson, Gary
    Lai, Chon
    Johansen, Andrea
    Miner, Jeff
    Vernier, Jean-Michel
    Girardet, Jean-Luc
    Quart, Barry
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S453 - S453
  • [2] RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer
    Iverson, Cory
    Larson, Gary
    Lai, Chon
    Yeh, Li-Tain
    Dadson, Claudia
    Weingarten, Paul
    Appleby, Todd
    Vo, Todd
    Maderna, Andreas
    Vernier, Jean-Michel
    Hamatake, Robert
    Miner, Jeffrey N.
    Quart, Barry
    CANCER RESEARCH, 2009, 69 (17) : 6839 - 6847
  • [3] The selective MEK inhibitor RDEA119: synergy with multiple classes of anti-cancer agents
    Chapman, Mark
    Iverson, Cory
    Miampamba, Marcel
    Yu, Chunrong
    Adjei, Alex
    Girardet, Jean-Luc
    Quart, Barry
    Miner, Jeffrey
    CANCER RESEARCH, 2009, 69
  • [4] MEK inhibitor RDEA119 suppresses inflammatory cytokine production induced by monosodium urate crystals
    Cheney, Wayne
    Larson, Gary
    Lai, Chon
    Miampamba, Marcel
    Walker, Heli
    Miner, Jeff
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S879 - S879
  • [5] Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts
    Chang, Qing
    Chapman, Mark S.
    Miner, Jeffrey N.
    Hedley, David W.
    BMC CANCER, 2010, 10
  • [6] Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts
    Qing Chang
    Mark S Chapman
    Jeffrey N Miner
    David W Hedley
    BMC Cancer, 10
  • [7] Selective MEK Inhibitor RDEA119 exhibits efficacy in orthotopic hepatoma models and cytostatic potential in multiple cell based models of cancer
    Miner, J.
    Yu, C.
    Iverson, C.
    Hamatake, R.
    Cheney, W.
    Chapman, M.
    Adjei, A.
    Quart, B.
    EJC SUPPLEMENTS, 2008, 6 (12): : 181 - 181
  • [8] BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus
    Liu, Dingxie
    Xing, Joanna
    Trink, Barry
    Xing, Mingzhao
    INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (12) : 2965 - 2973
  • [9] Sequential combination of the novel allosteric MEK1/2 inhibitor BAY 86-9766 (RDEA119) with the mTOR inhibitor rapamycin decelerates relapse of pancreatic tumors
    Teichmann, Nicole
    Trajkovic-Arsic, Mania
    Scholz, Arne
    Schmid, Roland M.
    Braren, Rickmer
    Siveke, Jens T.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [10] Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer.
    Gore, L.
    Lewis, K.
    Von Hoff, D. D.
    Weiss, G. J.
    Ramanathan, R. K.
    Adjei, A. A.
    Dy, G. K.
    Ma, W. W.
    Clendeninn, N. J.
    Leffingwell, D. P.
    Sheedy, B.
    Iverson, C.
    Miner, J. N.
    Shen, Z.
    Yeh, L.
    Dubowy, R. L.
    Jeffers, M.
    Rajagopalan, P.
    Weekes, C. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345